Trial Profile
A randomized phase II study of preoperative Herceptin [trastuzumab]/Navelbine [vinorelbine] versus Taxotere [docetaxel]/Carboplatin/Herceptin in early stage, HER-2 positive breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2016
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Trastuzumab (Primary) ; Vinorelbine (Primary) ; Carboplatin
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 03 Feb 2016 Pooled results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 04 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
- 16 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.